

AMENDMENTS

In the specification at page 8, first full paragraph:

In a preferred embodiment, the present invention is particularly useful for reducing kidney reuptake and retention of targeting protein conjugates during treatment with protein conjugates of ribonucleases such as an Onconase® (ranpirnase) or protein mammalian ribonuclease (RNase) with a molecular weight of 12,000 that can be purified from *Rana pipiens* oocytes and early embryos. Onconase causes potent inhibition of protein synthesis in a rabbit reticulocyte lysate (IC_{50} $10^{-11}M$) and when microinjected into *Xenopus* oocytes (IC_{50} $10^{-10}M$). Unlike other members of the RNase A superfamily, Onconase does not degrade oocyte rRNA. Upon binding to the cell surface receptors of sensitive cells and its cytosolic internalization, Onconase causes cell death as a result of potent protein synthesis inhibition by a mechanism involving inactivation of cellular RNA. Onconase is not inhibited by mammalian placental ribonuclease inhibitor and this may explain Onconase's enhanced cytotoxicity when compared to the mammalian enzymes.